A randomized, double-blind comparison of OROS® hydromorphone and controlled-release morphine for the control of chronic cancer pain

BMC Palliative Care

Volumn 7, Issue 1, 2008, Pages

  Hanna, Magdi ^a,b   Thipphawong, John ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Analgesics and Pain Research   (United Kingdom)

^c M4 2A   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROMORPHONE; MORPHINE; MORPHINE SULFATE; OROS; UNCLASSIFIED DRUG;

ADULT; ANALGESIA; ANEMIA; ANOREXIA; ANXIETY; ARTICLE; ASTHENIA; BRIEF PAIN INVENTORY; CANCER PAIN; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN ASSESSMENT; PERIPHERAL EDEMA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 60649109218     PISSN: None     EISSN: 1472684X     Source Type: Journal    
DOI: 10.1186/1472-684X-7-17     Document Type: Article

References (39)

1. Cancer pain management according to WHO analgesic guidelines. SA Schug D Zech U Dorr, J Pain Symptom Manage 1990 5 27 32 10.1016/S0885-3924(05)80006-5 2324558
2. Field-testing of the WHO guidelines for cancer pain relief. Summary report of demonstration projects. V Ventafridda A Caraceni A Gamba, Advances in Pain Research and Therapy New York: Raven Press, Ltd., Foley KM, Bonica JJ, Ventafridda V, 1990 451 64
3. Cancer pain relief and palliative care. World Health Organization, Report of a WHO Expert Committee. Technical Report Series 804 Geneva, Switzerland: World Health Organization 1990 1 75 http://www.who.int/en/
4. Morphine and alternative opioids in cancer pain: the EAPC recommendations. GW Hanks F Conno N Cherny M Hanna E Kalso HJ McQuay S Mercadante J Meynadier P Poulain C Ripamonti L Radbruch JR Casas J Sawe RG Twycross V Ventafridda, Br J Cancer 2001 84 587 93 10.1054/bjoc.2001.1680 11237376
5. American Pain Society, Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain Glenview, IL: American Pain Society 5 2003 http://www.ampainsoc.org/pub/principles.htm
6. Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain. M Palangio DW Northfelt RK Portenoy D Brookoff RT Doyle Jr BE Dornseif MC Damask, J Pain Symptom Manage 2002 23 355 68 10.1016/S0885-3924(02)00390-1 12007754
7. Pharmacodynamics of orally administered sustained-release hydromorphone in humans. MS Angst DR Drover J Lotsch B Ramaswamy S Naidu DR Wada DR Stanski, Anesthesiology 2001 94 63 73 10.1097/00000542-200101000-00014 11135723
8. Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. DR Drover MS Angst M Valle B Ramaswamy S Naidu DR Stanski D Verotta, Anesthesiology 2002 97 827 36 10.1097/00000542-200210000-00013 12357147
9. Gastrointestinal safety of an extended-release, nondeformable, oral dosage form (OROS: a retrospective study). DM Bass M Prevo DS Waxman, Drug Saf 2002 25 1021 33 10.2165/00002018-200225140-00004 12408733
10. Formulation aspects in the development of osmotically controlled oral drug delivery systems. RJ Verma DM Krishna S Garg, J Controlled Release 2002 79 7 27 10.1016/S0168-3659(01)00550-8
11. Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence and absence of food. G Sathyan E Xu J Thipphawong SK Gupta, BMC Clin Pharmacol 2007 7 2 17270055 10.1186/1472-6904-7-2
12. Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence of alcohol. G Sathyan K Sivakumar J Thipphawong, Curr Med Res Opin 2008 24 297 305 10.1185/030079908X253861 18062845
13. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. RL Daut CS Cleeland RC Flanery, Pain 1983 17 197 210 10.1016/0304-3959(83)90143-4 6646795
14. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. MF Folstein SE Folstein PR McHugh, J Psychiatr Res 1975 12 189 98 10.1016/0022-3956(75)90026-6 1202204
15. Toxicity and response criteria of the Eastern Cooperative Oncology Group. MM Oken RH Creech DC Tormey J Horton TE Davis ET McFadden PP Carbone, Am J Clin Oncol 1982 5 649 55 10.1097/00000421-198212000-00014 7165009
16. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. RC Serlin TR Mendoza Y Nakamura KR Edwards CS Cleeland, Pain 1995 61 277 84 10.1016/0304-3959(94)00178-H 7659438
17. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. G Piaggio DR Elbourne DG Altman SJ Pocock SJ Evans, JAMA 2006 295 1152 60 10.1001/jama.295.10.1152 16522836
18. Superiority, equivalence, and non-inferiority trials. E Lesaffre, Bull NYU Hosp Jt Dis 2008 66 2 150 4 18537788
19. Methodology of superiority vs. equivalence trials and non-inferiority trials. E Christensen, J Hepatol 2007 46 5 947 54 10.1016/j.jhep.2007.02.015 17412447
20. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. S Keller CM Bann SL Dodd J Schein TR Mendoza CS Cleeland, Clin J Pain 2004 20 309 18 10.1097/00002508-200409000-00005 15322437
21. Pain and its treatment in outpatients with metastatic cancer. CS Cleeland R Gonin AK Hatfield JH Edmonson RH Blum JA Stewart KJ Pandya, N Engl J Med 1994 330 9 592 6 10.1056/NEJM199403033300902 7508092
22. Pain assessment: global use of the Brief Pain Inventory. CS Cleeland KM Ryan, Ann Acad Med Singapore 1994 23 129 38 8080219
23. Cancer Pain. J Graham M Fletcher-Louis, Decision Resources, Inc 2004 ii 175 http://www.decisionresources.com/
24. Barriers to cancer pain relief: fear of tolerance and addiction. JA Paice C Toy S Shott, J Pain Symptom Manage 1998 16 1 9 10.1016/S0885-3924(98)00025-6 9707652
25. Mild cognitive impairment: Clinical characterization and outcome. RC Petersen GE Smith SC Waring RJ Ivnik EG Tangalos E Kokmen, Arch Neurol 1999 56 303 8 10.1001/archneur.56.3.303 10190820
26. Hydromorphone for acute and chronic pain. C Quigley, Cochrane Database Syst Rev 2002 1 CD003447 11869661
27. A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. M Moriarty CJ McDonald AJ Miller, J Drug Assessment 1999 2 41 8
28. Summary of Product Characteristics for JURNISTA. ALZA Corporation, Mountain View, CA
29. Opioid analgesics and antagonists. T Reisine G Pasternak, Goodman & Gilman's The Pharmacological Basis of Therapeutics New York: McGraw-Hill, Hardman JG, Gilman AG, Limbird LE, 1996 521 55
30. Hydromorphone: pharmacology and clinical applications in cancer patients. N Sarhill D Walsh KA Nelson, Support Care Cancer 2001 9 84 96 10.1007/s005200000183 11305075
31. Molecular biology of opioid analgesia. GW Pasternak, J Pain Symptom Manage 2005 29 S2 S9 10.1016/j.jpainsymman.2005.01.011 15907642
32. The endogenous opioid system and clinical pain management. JE Holden Y Jeong JM Forrest, AACN Clin Issues 2005 16 291 301 16082232
33. Are μ-opioid receptor polymorphisms important for clinical opioid therapy? J Lötsch G Geisslinger, Trends Mol Med 2005 11 82 9 10.1016/j.molmed.2004.12.006 15694871
34. Clinical pharmacology and pharmacotherapy of opioid switching in cancer patients. JR Ross J Riley C Quigley KI Welsh, Oncologist 2006 11 7 765 73 10.1634/theoncologist.11-7-765 16880235
35. Management of expected and unexpected opioid-related side effects. JD Harris, Clin J Pain 2008 24 Suppl 10 S8 S13 18418226
36. Current developments in opioid therapy for management of cancer pain. OA de Leon-Casasola, Clin J Pain 2008 24 Suppl 10 S3 S7 18418225
37. Opioid rotation from oral morphine to oral oxycodone in cancer patients with intolerable adverse effects: an open-label trial. M Narabayashi Y Saijo S Takenoshita M Chida N Shimoyama T Miura K Tani K Nishimura Y Onozawa T Hosokawa T Kamoto T Tsushima Advisory Committee for Oxycodone Study, Jpn J Clin Oncol 2008 38 4 296 304 10.1093/jjco/hyn010 18326541
38. New strategies in opioid therapy for cancer pain. N Cherny, J Oncol Manag 2000 9 8 15 10787576
39. Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. BH McCarberg RL Barkin, Am J Ther 2001 8 181 6 10.1097/00045391-200105000-00006 11344385